Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...

Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether Capricor Therapeutics (NASDAQ:CAPR) ...

Capricor Therapeutics (CAPR) shares soared 12% in the last trading session to close at $6.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. BOSTON — Replimune Group and ...

LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors of a class action representing investors ...

High-rolling investors have positioned themselves bearish on Capricor Therapeutics (NASDAQ:CAPR), and it's important for retail traders to take note. \This activity came to our attention today through ...

(RTTNews) - Biotechnology company Capricor Therapeutics (CAPR) Thursday announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...